|Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms|
MC Rodriguez-Oroz, M Jahanshahi, P Krack, I Litvan, R Macias, E Bezard, ...
The Lancet Neurology 8 (12), 1128-1139, 2009
|Pathophysiology of levodopa-induced dyskinesia: potential for new therapies|
E Bezard, JM Brotchie, CE Gross
Nature Reviews Neuroscience 2 (8), 577, 2001
|Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned macaque …|
E Bezard, S Dovero, C Prunier, P Ravenscroft, S Chalon, D Guilloteau, ...
Journal of Neuroscience 21 (17), 6853-6861, 2001
|Priorities in Parkinson's disease research|
WG Meissner, M Frasier, T Gasser, CG Goetz, A Lozano, P Piccini, ...
Nature reviews Drug discovery 10 (5), 377, 2011
|Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function|
E Bézard, S Ferry, U Mach, H Stark, L Leriche, T Boraud, C Gross, ...
Nature medicine 9 (6), 762, 2003
|Increased D1 dopamine receptor signaling in levodopa‐induced dyskinesia|
I Aubert, C Guigoni, K Håkansson, Q Li, S Dovero, N Barthe, BH Bioulac, ...
Annals of Neurology: Official Journal of the American Neurological …, 2005
|Lewy body extracts from Parkinson disease brains trigger α‐synuclein pathology and neurodegeneration in mice and monkeys|
A Recasens, B Dehay, J Bové, I Carballo‐Carbajal, S Dovero, ...
Annals of neurology 75 (3), 351-362, 2014
|Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders|
V Voon, PO Fernagut, J Wickens, C Baunez, M Rodriguez, N Pavon, ...
The Lancet Neurology 8 (12), 1140-1149, 2009
|Presymptomatic compensation in Parkinson's disease is not dopamine-mediated|
E Bezard, CE Gross, JM Brotchie
Trends in neurosciences 26 (4), 215-221, 2003
|Novel pharmacological targets for the treatment of Parkinson's disease|
AHV Schapira, E Bezard, J Brotchie, F Calon, GL Collingridge, B Ferger, ...
Nature reviews Drug discovery 5 (10), 845, 2006
|The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders|
P Sokoloff, J Diaz, BL Foll, O Guillin, L Leriche, E Bezard, C Gross
CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS …, 2006
|Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives|
AHV Schapira, CW Olanow, JT Greenamyre, E Bezard
The Lancet 384 (9942), 545-555, 2014
|Electrophysiological and metabolic evidence that high-frequency stimulation of the subthalamic nucleus bridles neuronal activity in the subthalamic nucleus and the substantia …|
C Tai, T Boraud, E Bezard, B Bioulac, C Gross, A Benazzouz
The FASEB journal 17 (13), 1820-1830, 2003
|Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter|
E Bezard, CE Gross, MC Fournier, S Dovero, B Bloch, M Jaber
Experimental neurology 155 (2), 268-273, 1999
|High frequency stimulation of the internal Globus Pallidus (GPi) simultaneously improves parkinsonian symptoms and reduces the firing frequency of GPi neurons in the MPTP …|
T Boraud, E Bezard, B Bioulac, C Gross
Neuroscience letters 215 (1), 17-20, 1996
|Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease|
MF Bastide, WG Meissner, B Picconi, S Fasano, PO Fernagut, M Feyder, ...
Progress in neurobiology 132, 96-168, 2015
|A brain–spine interface alleviating gait deficits after spinal cord injury in primates|
M Capogrosso, T Milekovic, D Borton, F Wagner, EM Moraud, ...
Nature 539 (7628), 284, 2016
|Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach|
E Bezard, CE Gross
Progress in neurobiology 55 (2), 93-116, 1998
|Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of l-DOPA-induced dyskinesia|
A Muñoz, Q Li, F Gardoni, E Marcello, C Qin, T Carlsson, D Kirik, ...
Brain 131 (12), 3380-3394, 2008
|Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey|
T Boraud, E Bezard, B Bioulac, CE Gross
Brain 124 (3), 546-557, 2001